secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001999371-25-016108
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix reports preliminary Q3 net loss $32M, plans Tonmya launch by Nov 2025
---------------------------------------------------------------------------

- Preliminary Q3 2025 net loss ~$32.0M vs $14.2M YoY; net revenue $3.3M vs $2.8M.
- Cash and equivalents ~$190.1M at Sept 30, 2025; net operating cash use $28.8M.
- Subsequent equity offerings net $29.3M; cash runway into Q1 2027.
- U.S. commercial launch of Tonmya for fibromyalgia expected by end of Nov 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/0001999371-25-016108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125016108/tnxp_8k-102725.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-016108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer